22157.jpg
Global Molecular Diagnostics for Infectious Disease Market Report 2021-2025: Microbiology Lab May Disappear While Multiplex Takes Center Stage
05 mai 2021 04h53 HE | Research and Markets
Dublin, May 05, 2021 (GLOBE NEWSWIRE) -- The "Molecular Diagnostics for Infectious Disease 2021-2025: Market Analysis by Syndrome, Plex, Place, and Country with COVID-19 Impact & Forecast,...
22157.jpg
Molecular Diagnostics for Infectious Disease Markets, 2025 - C19Dx Demand Sweeps Over the Globe
29 janv. 2021 04h13 HE | Research and Markets
Dublin, Jan. 29, 2021 (GLOBE NEWSWIRE) -- The "Molecular Diagnostics for Infectious Disease By Syndrome, Plex, Place and by Country. With COVID-19 Impact & Forecasting/Analysis, and Executive...
22157.jpg
The Global Market for Molecular Diagnostics Infectious Disease 2021-2025
24 nov. 2020 17h23 HE | Research and Markets
Dublin, Nov. 24, 2020 (GLOBE NEWSWIRE) -- The "Molecular Diagnostics for Infectious Disease By Syndrome, Plex, Place and by Country. With COVID-19 Impact & Forecasting/Analysis, and Executive...
ContraFect_LOGO_Web.jpg
ContraFect Announces Plan for a Single Phase 3 Superiority Design Study of Exebacase Following Successful End-of-Phase 2 Meeting with FDA
02 oct. 2019 07h00 HE | ContraFect Corporation
Primary Endpoint of Clinical Response at Day 14 in Patients with Methicillin-Resistant Staph aureus (MRSA) Bacteremia, including Right-Sided Endocarditis Study Initiation Planned by Year-End 2019 ...
ContraFect_LOGO_Web.jpg
ContraFect Awarded $7.2 Million USAMRDC Grant to Support the Advancement of Lysin Candidate CF-296
06 juin 2019 07h00 HE | ContraFect Corporation
YONKERS, N.Y., June 06, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of biologic therapies for...
ContraFect_LOGO_Web.jpg
ContraFect Announces Presentation at the International Society of Cardiovascular Infectious Diseases Symposium
03 juin 2019 07h00 HE | ContraFect Corporation
YONKERS, N.Y., June 03, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of biologic therapies for...
ContraFect_LOGO_Web.jpg
ContraFect Announces Publication of Paper on Recent Exebacase Data in Antimicrobial Agents and Chemotherapy Journal
31 mai 2019 07h00 HE | ContraFect Corporation
YONKERS, N.Y., May 31, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of biologic therapies for...
ContraFect_LOGO_Web.jpg
ContraFect to Present at Cantor Antibiotics Summit
11 janv. 2018 07h00 HE | ContraFect Corporation
YONKERS, N.Y., Jan. 11, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect_LOGO_Web.jpg
ContraFect to Present at 10th Annual Biotech Showcase
03 janv. 2018 07h00 HE | ContraFect Corporation
YONKERS, N.Y., Jan. 03, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...
ContraFect_LOGO_Web.jpg
ContraFect to Present at the 29th Annual Piper Jaffray Healthcare Conference
15 nov. 2017 07h00 HE | ContraFect Corporation
YONKERS, N.Y., Nov. 15, 2017 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...